Advertisement
| direct observation therapy tb: WHO consolidated guidelines on tuberculosis. Module 4 World Health Organization, 2022-04-30 Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community. |
| direct observation therapy tb: Treatment of Tuberculosis World Health Organization, 1993 |
| direct observation therapy tb: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care World Health Organization, 2017-06 The update of the Guidelines for Treatment of Drug-susceptible Tuberculosis and Patient Care is important in the context of the End TB Strategy, which recommends treatment and patient support for all people with TB. This update aims to use the best available evidence on the treatment of drug-susceptible TB and interventions to ensure adequate patient care and support in order to inform policy decisions made in these technical areas by national TB control program managers, national policy-makers, and medical practitioners in a variety of geographical, economic, and social settings. The objectives of these updated guidelines are to provide updated recommendations based on newly emerged evidence on the treatment of drug-susceptible TB and patient care as well as provide a summary of changes in the new guidelines with all the existing and valid WHO recommendations on the treatment of drug-susceptible TB and TB patient care. The key audience for these guidelines are policy-makers in ministries of health or managers of national TB programs who formulate country-specific TB treatment guidelines or who plan TB treatment programs. In addition, health professionals - including doctors, nurses, and educators working both in government services and nongovernmental organizations, such as technical agencies that are treating patients and organizing treatment services - will find these guidelines to be useful. |
| direct observation therapy tb: Guidance on Ethics of Tuberculosis Prevention, Care and Control World Health Organization, 2015-04-20 With the growing breadth and complexity of TB efforts today comes a greater range of concerns associated with the ethics of action, inaction and specific approaches to clinical, public health and research interventions. In 2006, the documented emergence of extensively drug-resistant tuberculosis (XDR-TB),2 including a dramatic and lethal outbreak in South Africa, brought forward urgent issues of public health ethics given the imposition in some programs of involuntary detention of persons suspected and/or confirmed of being ill with drug-resistant TB under the justification of public safety. In a linked effort, the Stop TB Partnership agreed to establish a TB and Human Rights Task Force in 2010, with secretariat being provided by WHO and the Joint United Nations Program on HIV/AIDS (UNAIDS). The Task Force will aim to develop a policy framework for a rights-based approach to TB prevention, care and control as joint products of WHO, the Stop TB Partnership and UNAIDS. It will also propose a strategic agenda for action. It will be composed of major stakeholders, constituencies from affected communities and risk groups, human rights and civil society organizations, health and human rights experts, United Nations agencies, and development partners. This ethics guidance and the resulting rights-based policy framework will be used as complementary and companion documents to guide further dialogue and action in these areas. |
| direct observation therapy tb: Disease Control Priorities, Third Edition (Volume 6) King K. Holmes, Stefano Bertozzi, Barry R. Bloom, Prabhat Jha, 2017-11-06 Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings. |
| direct observation therapy tb: Tuberculosis in the Workplace Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee on Regulating Occupational Exposure to Tuberculosis, 2001-05-15 Before effective treatments were introduced in the 1950s, tuberculosis was a leading cause of death and disability in the United States. Health care workers were at particular risk. Although the occupational risk of tuberculosis has been declining in recent years, this new book from the Institute of Medicine concludes that vigilance in tuberculosis control is still needed in workplaces and communities. Tuberculosis in the Workplace reviews evidence about the effectiveness of control measuresâ€such as those recommended by the Centers for Disease Control and Preventionâ€intended to prevent transmission of tuberculosis in health care and other workplaces. It discusses whether proposed regulations from the Occupational Safety and Health Administration would likely increase or sustain compliance with effective control measures and would allow adequate flexibility to adapt measures to the degree of risk facing workers. |
| direct observation therapy tb: Disease Control Priorities in Developing Countries Dean T. Jamison, Joel G. Breman, Anthony R. Measham, George Alleyne, Mariam Claeson, David B. Evans, Prabhat Jha, Anne Mills, Philip Musgrove, 2006-04-02 Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries. |
| direct observation therapy tb: Guidelines for the Programmatic Management of Drug-resistant Tuberculosis World Health Organization, 2008 The emergence of extensively drug-resistant strains of tuberculosis, especially in countries with a high prevalence of human immunodeficiency virus, is a serious threat to global public health and jeopardizes efforts to effectively control the disease. This publication offers updated recommendations for the diagnosis and management of drug-resistant tuberculosis in a variety of geographical, economic and social settings, and the recording of data that enables the monitoring and evaluation of programs.--Publisher's description. |
| direct observation therapy tb: Global Tuberculosis Control World Health Organization, 2008 WHO's twelfth annual report on global tuberculosis control in a series that started in 1997. |
| direct observation therapy tb: Tuberculosis in Adults and Children Dorothee Heemskerk, Maxine Caws, Ben Marais, Jeremy Farrar, 2015-07-17 This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases. |
| direct observation therapy tb: Netter's Infectious Diseases - E-Book Elaine C. Jong, Dennis L. Stevens, 2021-03-19 Widely used by students, residents, generalists, and specialists, Netter's Infectious Diseases, 2nd Edition delivers must-know information on infectious diseases in a highly illustrated, easily accessible format. Concise visual overviews of essential topics provide a convenient, trustworthy way to review the basics of a given infectious disease or issue or to share with patients or staff. Drs. Elaine Jong and Dennis Stevens cover the wide spectrum of illness and disease in this complex field using memorable illustrations by world-renowned artist Frank H. Netter and others, offering a time-saving, authoritative look at infectious disease risk factors, clinical presentations, pathophysiology, and more. - Covers major conditions and problems such as vaccine-preventable diseases, drug-resistant staph, community acquired pneumonia, surgical infections, pyelonephritis, viral hepatitis, and sexually transmitted infections—and provides updated approaches to diagnosis, treatment, prevention, and standards of care. - Includes new clinical vignettes added to most chapters - Provides updated and expanded coverage of emerging infectious diseases such as multidrug resistant tuberculosis (MDR-TB), neuroangiostrongyliasis (rat lungworm disease), Ebola virus, Severe Acute Respiratory Disease (SARS), Middle East Respiratory Syndrome (MERS), Coronavirus Infectious Disease-2019 (COVID-19), and novel influenza viruses including public health concerns. - Covers vector-borne diseases including malaria, yellow fever, Zika infections and congenital Zika syndrome, West Nile fever, Lyme disease, tick-borne encephalitis, and Chagas disease plus others. - New chapters on travelers' diarrhea, cholera, and primary amebic meningoencephalitis debut in the section on international travel and outdoor activities. - Contains memorable parasite life cycles and unforgettable parasite infection clinical vignettes. - Features unparalleled illustrations by Drs. Frank H. Netter, Carlos Machado, and others, as well as radiologic images. - Provides 24 printable patient education brochures in the digital ebook. |
| direct observation therapy tb: WHO consolidated guidelines on drug-resistant tuberculosis treatment World Health Organization, 2018-11-07 Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by the End TB Strategy of the World Health Organization (WHO). There is thus a critical need for evidence-based policy recommendations on the treatment and care of patients with DR-TB, based on the most recent and comprehensive evidence available. In this regard, the WHO consolidated guidelines on drug-resistant tuberculosis treatment fulfil the mandate of WHO to inform health professionals in Member States on how to improve treatment and care for patients with DR-TB. Between 2011 and 2018, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update, issued by WHO in December 2018. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups (GDGs), using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. |
| direct observation therapy tb: Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children World Health Organization, 2015-02-05 It is estimated that one third of the world's population is infected with Mycobacterium tuberculosis (the bacterium that causes tuberculosis (TB)), and that each year, about 9 million people develop TB, of whom about 2 million die. Of the 9 million annual TB cases, about 1 million (11%) occur in children (under 15 years of age). Of these childhood cases, 75% occur annually in 22 high-burden countries that together account for 80% of the world's estimated incident cases. In countries worldwide, the reported percentage of all TB cases occurring in children varies from 3% to more than 25%. The Stop TB Strategy, which builds on the DOTS strategy developed by the World Health Organization (WHO) and the International Union Against TB and Lung Disease, has a critical role in reducing the worldwide burden of disease and thus in protecting children from infection and disease. The management of children with TB should be in line with the Stop TB Strategy, taking into consideration the particular epidemiology and clinical presentation of TB in children. These consensus guidelines were produced to help the National Tuberculosis Programmes on the management of tuberculosis in children. |
| direct observation therapy tb: Toman's Tuberculosis K. Toman, World Health Organization, 2004-06-23 This is the second edition of a reference work aimed at all those concerned with dealing with tuberculosis control in developing countries. The book follows in the tradition of Kurt Toman's original work in this field, with the text set out in a question and answer format, grouped under three headings: case detection; treatment, and monitoring. The threat of tuberculosis is still potent, with two million deaths globally. This new edition, containing contributions from a number of experts in this field, addresses the resurgence of tuberculosis, and the emergence of multidrug-resistant bacilli, and the growth of HIV-infected individuals with tuberculosis, as well as recent scientific developments. |
| direct observation therapy tb: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis World Health Organization, 2015-04-20 This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly's resolution on prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Resolution WHA62.15, adopted in 2009, calls on Member States to develop a comprehensive framework for the management and care of patients with drug-resistant TB. The recommendations contained in these guidelines address the most topical questions concerning the programmatic management of drug-resistant TB: case-finding, multidrug resistance, treatment regimens, monitoring the response to treatment, and selecting models of care. The guidelines primarily target staff and medical practitioners working in TB treatment and control, and partners and organizations providing technical and financial support for care of drug-resistant TB in settings where resources are limited. |
| direct observation therapy tb: Interventions for Tuberculosis Control and Elimination Hans L. Rieder, 2002 |
| direct observation therapy tb: HIV-related TB. , 1993 |
| direct observation therapy tb: Comprehensive Handbook of Alcohol Related Pathology Victor R. Preedy, Ronald Ross Watson, 2004-12-24 This comprehensive handbook is a one-stop-shop for all researchers involved in the field of alcohol-related harm at the whole body or cellular level. Over 100 chapters provide abundant information of a wide range of topics that extend from the evolutionary aspects of alcohol consumption and the prevalence of alcohol misuse to programmed cell death. Each chapter is highly illustrated with tables and figures making this a valuable reference for students, clinicians and researchers alike. *Over 100 chapters conveniently divided into 3 sections *Represents a 'one-stop-shop' of information with suitable indexing of the various pathways and processes *Each chapter is highly illustrated with tables as well as figures |
| direct observation therapy tb: Ending Neglect Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee on the Elimination of Tuberculosis in the United States, 2000-08-31 Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the worldâ€ominously, in forms resistant to commonly used medicines. What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action. The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response. The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB. |
| direct observation therapy tb: Antibiotic and Chemotherapy Roger G. Finch, 2003 The completely revised and updated New Edition of this respected resource presents globally-relevant coverage of all types of antimicrobial agents used in human medicine, providing authoritative guidance on the principles and practice of antimicrobial chemotherapy. In addition to full coverage of every commonly used antibiotic agent, it includes complete coverage of all antiviral, antiprotozoan and anthelminthic agents. And, its unique 3-part structure makes it easy to locate information: Part I covers general aspects of treatment; Part II reviews every agent, including antimicrobial activity, pharmacokinetics, clinical use, and available preparations; Part III details the treatment of particular infections. Discusses the increasing problem of multi-drug resistance and the wide range of new antiviral therapies now available for the treatment of HIV and other viral infections. Reviews all of the new antimicrobial agents in detail. Features more clinically focused sections on Pharmacokinetics. Details new antifungal therapies, including voriconazole, liposomal, and amphotericin B. Presents new tables on major drug interactions, placental transfer, and concentrations of agents in breast milk. Features new sections on liver failure, drug development and licensing, and the implications of xenotransplantation. Presents expanded coverage of Quinolone as well as new antimalarial combination therapies. Offers cross-references to key web sites, for up-to-date information on treatment and drug resistance. |
| direct observation therapy tb: Healthcare Access Umar Bacha, Urška Rozman, Sonja Šostar Turk, 2020-05-27 Healthcare Access - Regional Overviews is a compilation of ten chapters consisting of case studies, research works, reviews, and expert opinions providing insight on the previous and current developments in the field of hygiene and infection control with practices to prevent or minimize the spread of infectious diseases. The book also addresses the status and healthcare access of the most neglected segments in less developed countries. All chapters are written by global researchers are edited by experts in the field. The information presented in this work can be replicated at different levels to accelerate timely and quality healthcare services. |
| direct observation therapy tb: Revolutionizing Tropical Medicine Kerry Atkinson, Prof. David Mabey, 2019-08-27 A comprehensive resource describing innovative technologies and digital health tools that can revolutionize the delivery of health care in low- to middle-income countries, particularly in remote rural impoverished communities Revolutionizing Tropical Medicine offers an up-to-date guide for healthcare and other professionals working in low-resource countries where access to health care facilities for diagnosis and treatment is challenging. Rather than suggesting the expensive solution of building new bricks and mortar clinics and hospitals and increasing the number of doctors and nurses in these deprived areas, the authors propose a complete change of mindset. They outline a number of ideas for improving healthcare including rapid diagnostic testing for infectious and non-infectious diseases at a point-of-care facility, together with low cost portable imaging devices. In addition, the authors recommend a change in the way in which health care is delivered. This approach requires task-shifting within the healthcare provision system so that nurses, laboratory technicians, pharmacists and others are trained in the newly available technologies, thus enabling faster and more appropriate triage for people requiring medical treatment. This text: Describes the current burden of communicable and non-communicable diseases in low- to middle-income countries throughout the world Describes the major advances in healthcare outcomes in low-to middle-income countries derived from implementation of the United Nations/World Health Organisation’s 2000 Millennium Development Goals Provides a review of inexpensive rapid diagnostic point-of-care tests for infectious diseases in low-resource countries, particularly for people living in remote rural areas Provides a review of other rapid point-of-care services for assessing hematological function, biochemical function, renal function, hepatic function and status including hepatitis, acid-base balance, sickle cell disease, severe acute malnutrition and spirometry Explores the use of low-cost portable imaging devices for use in remote rural areas including a novel method of examining the optic fundus using a smartphone and the extensive value of portable ultrasound scanning when x-ray facilities are not available Describes the use of telemedicine in the clinical management of both children and adults in remote rural settings Looks to the future of clinical management in remote impoverished rural settings using nucleic acid identification of pathogens, the use of nanoparticles for water purification, the use of drones, the use of pulse oximetry and the use of near-infrared spectroscopy Finally, it assesses the potential for future healthcare improvement in impoverished areas and how the United Nations/World Health Organization 2015 Sustainable Development Goals are approaching this. Written for physicians, infectious disease specialists, pathologists, radiologists, nurses, pharmacists and other health care workers, as well as government healthcare managers, Revolutionizing Tropical Medicine is a new up-to-date essential and realistic guide to treating and diagnosing patients in low-resource tropical countries based on new technologies. |
| direct observation therapy tb: Management of MDR-TB World Health Organization, 2009 Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are increasingly encountered in resource-limited settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centers) will need to diagnose MDR-TB, initiate second-line anti-TB drugs, and monitor MDR-TB treatment. This Field Guide was created to help health workers carry out these tasks. It is a job aid that medical officers and TB nurses are meant to use frequently during the day for quick reference. It is based on the Emergency Update 2008 of Guidelines for Programmatic Management of Drug-resistant Tuberculosis, and may be considered a companion document to these guidelines. It also draws on the experience of the international health NGO Partners In Health (PIH) in many countries. This module should be introduced to health workers in the context of a training course with a strong emphasis on TB-HIV co-management. |
| direct observation therapy tb: Drug Monitoring and Clinical Chemistry Georg Hempel, 2004-05-15 Drug Monitoring and Clinical Chemistry, the 5th volume in the Handbook of Analytical Separations series, gives an overview about methods to analyse drugs in biological fluids. The most widely used methods to analyse drugs in biological fluids. i.e. chromatographic methods, CE and immunoassays are described in detail. For important drugs, an overview about the methods available and a comparison of the techniques should be given to enable the reader to choose the right method depending on laboratory equipment, staff, the aim of the investigation etc. Other general aspects important for conducting therapeutic drug monitoring or pharmacokinetics studies are also covered, i.e. sample preparation, validation of the analytical methods and pharmacokinetic methods for interpreting the data. Areas where therapeutic drug monitoring is used frequently such as antibiotics, immunosuppressant drugs, antipsychotic and anticancer drugs will be discussed in detail. In addition, the important field of phenotyping and genotyping for therapy optimisation with special focus on real-life applications is also covered. The book contains important information for analyst working on drug analysis in clinical chemistry, hospital pharmacists involved in therapeutic drug monitoring, other pharmacists, chemists or physicians working on pharmacokinetic studies in industry or academia. In contrast to other books in this field, this book provides up-to-date information regarding both methodology and clinical applications. For the applications, only fields are described where therapeutic drug monitoring is used in clinical routine and provides benefit to the patients. - Overview of all important field where therapeutic drug monitoring is applied - All relevant analytical and computational methods are discussed - Written by experts with a lot of practical experience in the field |
| direct observation therapy tb: Global Tuberculosis Control World Health Organization, 2010 The World Health Organization (WHO) has published an annual report on global control of tuberculosis (TB) every year since 1997. The main purpose of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress made in TB care and control at global, regional and country levels. This fifteenth annual report contains more up-to-date information than any previous report in the series, following earlier data collection and the completion of the production cycle within a calendar year. This report includes the same wealth of information as previous reports in the series, but three new features are worth highlighting. First, the data are more up-to-date than those included in previous reports. Data up to and including 2009 are presented for almost all key indicators; financial data extend to 2011. Second, results from several analyses undertaken for the first time in 2010 are included. Examples are: (i) for each of the 22 high-burden countries (HBCs), trends in rates of TB incidence and mortality since 1990 combined with projections of whether the target of halving the 1990 mortality rate by 2015 will be achieved; (ii) estimates of the lives saved by TB control between 1995 and 2009 and projections of the additional lives that could be saved up to 2015, including separate estimates for women and children; (iii) assessment of progress in implementing and financing TB care and control against the targets included in a just-released and updated version of the Global Plan to Stop TB; and (iv) a new and compelling compilation of data showing the contribution that PP PP M can make to case detection. Third, country profiles are available for all countries (rather than the 22 HBCs only) and can be downloaded online at www.who.int/tb/data, always drawing on the latest data available in WHO s global TB database. Annex 1 explains the methods that were used to produce estimates of disease burden. Annex 2 contains summary tables that provide global, regional and country-specific data for the main indicators of interest. Country profiles for all countries are available online at www.who.int/tb/data; their content is advertised in Annex 3. |
| direct observation therapy tb: Global Tuberculosis Report 2015 World Health Organization, 2015 Chapter 1. Introduction -- chapter 2. Disease burden and 2015 targets assessment -- chapter 3. TB case notifications and treatment outcomes -- chapter 4. Drug-resistant TB -- chapter 5. Diagnostics and laboratory strengthening -- chapter 6. Addressing the co-epidemics of TB and HIV -- chapter 7. Financing -- chapter 8. Research and development -- Annexes. |
| direct observation therapy tb: Discovering Tuberculosis Christian W. McMillen, 2015-06-28 Tuberculosis is one of the world’s deadliest infectious diseases, killing nearly two million people every year—more now than at any other time in history. While the developed world has nearly forgotten about TB, it continues to wreak havoc across much of the globe. In this interdisciplinary study of global efforts to control TB, Christian McMillen examines the disease’s remarkable staying power by offering a probing look at key locations, developments, ideas, and medical successes and failures since 1900. He explores TB and race in east Africa, in South Africa, and on Native American reservations in the first half of the twentieth century, investigates the unsuccessful search for a vaccine, uncovers the origins of drug-resistant tuberculosis in Kenya and elsewhere in the decades following World War II, and details the tragic story of the resurgence of TB in the era of HIV/AIDS. Discovering Tuberculosis explains why controlling TB has been, and continues to be, so difficult. |
| direct observation therapy tb: Global Health and the Future Role of the United States National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Global Health, Committee on Global Health and the Future of the United States, 2017-10-05 While much progress has been made on achieving the Millenium Development Goals over the last decade, the number and complexity of global health challenges has persisted. Growing forces for globalization have increased the interconnectedness of the world and our interdependency on other countries, economies, and cultures. Monumental growth in international travel and trade have brought improved access to goods and services for many, but also carry ongoing and ever-present threats of zoonotic spillover and infectious disease outbreaks that threaten all. Global Health and the Future Role of the United States identifies global health priorities in light of current and emerging world threats. This report assesses the current global health landscape and how challenges, actions, and players have evolved over the last decade across a wide range of issues, and provides recommendations on how to increase responsiveness, coordination, and efficiency †both within the U.S. government and across the global health field. |
| direct observation therapy tb: Adherence to Long-term Therapies Eduardo Sabaté, World Health Organization, 2003 This report is based on an exhaustive review of the published literature on the definitions, measurements, epidemiology, economics and interventions applied to nine chronic conditions and risk factors. |
| direct observation therapy tb: Genital Tuberculosis Gita Ganguly Mukherjee, Satchidananda Tripathy, Sindhu Nandini Tripathy, 2010-02-28 |
| direct observation therapy tb: Core Curriculum on Tuberculosis , 1991 |
| direct observation therapy tb: Systematic Screening for Active Tuberculosis World Health Organization, 2013 There have been calls to revisit the experiences of TB screening campaigns that were widely applied in Europe and North America in the mid-20th century, as well as more recent experiences with TB screening in countries with a high burden of the disease, and to assess their possible relevance for TB care and prevention in the 21st century. In response, WHO has developed guidelines on screening for active TB. An extensive review of the evidence has been undertaken. The review suggests that screening, if done in the right way and targeting the right people, may reduce suffering and death, but the review also highlights several reasons to be cautious. As discussed in detail in this book, there is a need to balance potential benefits against the risks and costs of screening; this conclusion is mirrored by the history of TB screening. This publication presents the first comprehensive assessment by WHO of the appropriateness of screening for active TB since the recommendations made in 1974 by the Expert Committee. However, the relative effectiveness and cost effectiveness of screening remain uncertain, a point that is underscored by the systematic reviews presented in this guideline. Evidence suggests that some risk groups should always be screened, whereas the prioritization of other risk groups as well as the choice of screening approach depend on the epidemiology, the health-system context, and the resources available. This book sets out basic principles for prioritizing risk groups and choosing a screening approach; it also emphasizes the importance of assessing the epidemiological situation, adapting approaches to local situations, integrating TB screening into other health-promotion activities, minimizing the risk of harm to individuals, and engaging in continual monitoring and evaluation. It calls for more and better research to assess the impact of screening and to develop and evaluate new screening tests and approaches. |
| direct observation therapy tb: Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income Countries World Health Organization, 2012 The main purpose of these recommendations is to assist national and local public health tuberculosis (TB) control programmes in low- and middle-income countries to develop and implement case finding among people exposed to infectious cases of TB. Systematic evaluation of people who have been exposed to potentially infectious cases of tuberculosis (TB) can be an efficient, targeted approach to intensified TB case finding that is within the purview of TB control programmes. There are, however, no comprehensive global recommendations for programmes. WHO, the International Union against Tuberculosis and Lung Disease and the International Standards for Tuberculosis Care all recommend that children under 5 years of age and persons living with HIV (PLHIV) who are exposed to infectious cases of TB be evaluated for active TB and considered for treatment of latent tuberculosis infection (LTBI) if active TB is excluded. With these exceptions, there are no recommendations at global level to: 1. define the epidemiological and programme conditions under which contact investigation is indicated;2. describe TB index patients on whom contact investigation should be focused;3. identify TB contacts who should be investigated (other than children under 5 years of age and PLHIV);and recommend the procedures to be used for identifying, screening and tracking TB contacts. The following recommendations are based on recent systematic reviews of the literature on contact investigation in low- and middle-income countries. |
| direct observation therapy tb: American Academy of Pediatrics Textbook of Pediatric Care Jane Meschan Foy, 2016-03-31 The definitive manual of pediatric medicine - completely updated with 75 new chapters and e-book access. |
| direct observation therapy tb: Global Tuberculosis Report 2014 World Health Organization, 2014 Some volumes for 2014 includes CD-ROM for 2014 key indicators. |
| direct observation therapy tb: Clinical Tuberculosis John Crofton, Norman Horne, Frederick John William Miller, 1992 |
| direct observation therapy tb: Ethics and Drug Resistance: Collective Responsibility for Global Public Health Euzebiusz Jamrozik, Michael Selgelid, 2021-08-21 This Open Access volume provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases. Antimicrobial resistance (AMR) is widely recognized to be one of the greatest threats to global public health in coming decades; and it has thus become a major topic of discussion among leading bioethicists and scholars from related disciplines including economics, epidemiology, law, and political theory. Topics covered in this volume include responsible use of antimicrobials; control of multi-resistant hospital-acquired infections; privacy and data collection; antibiotic use in childhood and at the end of life; agricultural and veterinary sources of resistance; resistant HIV, tuberculosis, and malaria; mandatory treatment; and trade-offs between current and future generations. As the first book focused on ethical issues associated with drug resistance, it makes a timely contribution to debates regarding practice and policy that are of crucial importance to global public health in the 21st century. |
| direct observation therapy tb: Global Tuberculosis Report 2016 World Health Organization, 2016 This global tuberculosis report is the first to be produced in the era of the SDGs and the End TB Strategy. It provides an assessment of the TB epidemic and progress in TB diagnosis, treatment, and prevention efforts as well as an overview of TB-specific financing and research. It also discusses the broader agenda of universal health coverage, social protection, and other SDGs that have an impact on health. Data was available for 202 countries and territories that account for over 99% of the world's population and TB cases. |
| direct observation therapy tb: Global Tuberculosis Report 2017 World Health Organization, 2017-12-13 WHO's Global Tuberculosis Report provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in care and prevention at global, regional and country levels. This is done in the context of recommended global TB strategies and associated targets, and broader development goals. For the period 2016-2035, these are WHO's End TB Strategy and the United Nations' (UN) Sustainable Development Goals (SDGs), which share a common aim: to end the global TB epidemic. The main data sources for the report are annual rounds of global TB data collection implemented by WHO's Global TB Program since 1995 and databases maintained by other WHO departments, UNAIDS and the World Bank. In WHO's 2017 round of global TB data collection, 201 countries and territories that account for over 99% of the world's population and TB cases reported data. |
| direct observation therapy tb: A Tuberculosis Guide for Specialist Physicians José A. Caminero Luna, 2003 |
Implementing an Electronic Directly Observed Therapy (eDOT) …
Directly observed therapy (DOT) is the most effective strategy for ensuring that tuberculosis (TB) patients adhere to treatment. DOT means that a health care worker or another designated …
Implementing Directly Observed Therapy for the Treatment of …
The purpose of this document is to outline standards when implementing DOT for persons on therapy for TB disease and known or suspected TB infection (known as directly observed …
Directly Observed Therapy (DOT) for the Treatment of …
National TB treatment guidelines strongly recommend using a patient-centered case management approach - including directly observed therapy (“DOT”) - when treating persons with active TB …
Information for Physicians Regarding Directly Observed …
Directly Observed Therapy (DOT) is a technique of delivering TB treatment to ensure timely completion of treatment, prevent further TB transmission, and prevent development of drug …
NYS Department of Health
Directly Observed Therapy for Tuberculosis (TB/DOT) is the direct observation of oral ingestion of TB medications to assure patient compliance with the prescribed medication regimen.
Direct Observational Therapy for the Treatment of …
Key Findings d six randomized controlled trials were identified regarding the clinical evidence for provision of direct observat onal therapy (DOT) for the treatment of tuberculosis. The evidence …
REVISITING DOT: BEST PRACTICES IN DIRECT OBSERVATION …
Direct Observation is a preferred practice for certain individuals with latent TB infections such as contacts, young children, or individuals with high risk factors to progress to active disease
DIRECTLY OBSERVED THERAPY (DOT) AGREEMENT FOR …
I will be taking several medications for a long time (6 months or more) in order to kill the TB bacteria. take my medicine and to make sure I complete my treatment and get well. In this …
Direct Observation Therapy For Tb - staging …
Module 4 World Health Organization,2022-04-30 Between 2011 and 2019 WHO has developed and issued evidence based policy recommendations on the treatment and care of patients with …
Using Directly Observed Therapy (DOT) with TB Treatment
practice of observing a patient swallow his or her tuberculosis (TB) medications. National guidelines recommend DOT as part of the standard of care for TB t. eatment, and DOT is used …
TB Directly Observed Therapy SDO - Texas Department of …
The purpose of this document is to provide authority for specific acts of tuberculosis (TB) directly observed therapy (DOT) services described by the TB and Hansen’s Disease Unit and under …
New Procedure Code for Directly Observed Therapy for
Effective for dates of service (DOS) on and after January 1, 2011, providers will be required to indicate separate Healthcare Common Procedure Coding System (HCPCS) procedure codes …
what is DOTS.PDF - World Health Organization
DOTS (Directly Observed Treatment, Short-course) is the most effective strategy available for controlling the TB epidemic today. DOTS has five key components: Government commitment …
Guidelines for Directly Observed Therapy Program Protocols …
DOT is the observation of a person taking his/her prescribed medication for the treatment of tuberculosis (TB) disease or TB infection. This requires a person who has received training in …
Wisconsin Electronic Video Directly Observed Therapy (eDOT)
Electronic DOT (eDOT ) is the use of electronic technologies to remotely monitor TB patients ingesting their medication, either in real time or recorded. The Wisconsin State TB Program will …
Recommendations for Use of Video Directly Observed …
Directly observed therapy (DOT) for tuberculosis treatment involves observing a patient ingest medication, monitoring the patient for adverse events, and providing support for treatment …
Dynamics of Tuberculosis: The effect of Direct Observation …
A global control strategy adopted by the WHO to help reduce the number of active TB cases as well as promote proper treatment of patients with tuberculosis is the Direct Observation …
Video-Enabled Directly Observed Therapy
This document describes the position of the Texas Department of State Health Services (DSHS) regarding the implementation of video-enabled directly observed therapy (VDOT), a supportive …
A COMPARISON OF DIRECT OBSERVATION OF TREATMENT …
The association between successful treatment outcome and recurrence of TB were measured with the following variables, method of direct observation of TB Therapy, employment status, …
Directly Observed Treatment, Short Course (DOTS): An overview
Aug 2, 2018 · DOTS (directly observed treatment, short-course.), is the name given to the tuberculosis control strategy recommended by the World Health Organization. According to …
Implementing an Electronic Directly Observed Therapy …
Directly observed therapy (DOT) is the most effective strategy for ensuring that tuberculosis (TB) patients adhere to treatment. DOT means that a health …
Implementing Directly Observed Therapy for the …
The purpose of this document is to outline standards when implementing DOT for persons on therapy for TB disease and known or suspected TB …
Directly Observed Therapy (DOT) for the Treatment o…
National TB treatment guidelines strongly recommend using a patient-centered case management approach - including directly observed therapy …
Information for Physicians Regarding Directly Observe…
Directly Observed Therapy (DOT) is a technique of delivering TB treatment to ensure timely completion of treatment, prevent further TB transmission, and …
NYS Department of Health
Directly Observed Therapy for Tuberculosis (TB/DOT) is the direct observation of oral ingestion of TB medications to assure patient …
